Neuronal Correlates of Altered States of Consciousness

LSD

Brief Summary

The aim of the present study is to assess the neuronal correlates of alterations in waking consciousness pharmacologically induced by a 5-hydroxytryptamine (HT)2A receptor agonist in healthy subjects using functional magnetic resonance imaging (fMRI).

Intervention / Treatment

  • Drug: LSD
  • Drug: Placebo

Condition or Disease

  • Healthy

Phase

Study Design

Study type: Interventional
Status: Completed
Study results: No Results Available
Age: 25 Years to 65 Years   (Adult, Older Adult)
Enrollment: 24 ()
Funded by: Other

Masking

Clinical Trial Dates

Start date: Dec 14, 2022
Primary Completion: Sep 15, 2022
Completion Date: Sep 15, 2022
Study First Posted: Dec 05, 2014
Results First Posted: Sep 25, 2020
Last Updated: Sep 25, 2015

Sponsors / Collaborators

Lead Sponsor: N/A
Responsible Party: N/A

Functional neuroimaging may be useful in the diagnosis and characterization of early schizophrenia. However, little is known about how the subjectively experienced alterations in consciousness and perception are related with objective neuroimaging measures. The present study explores the association of subjective alterations and objective imaging findings and will inform us on the neuronal correlates of psychotic states and whether subjective alterations in perception translate into neuronal activation patterns that can be objectively measured in a brain scanner. Therefore, alterations in consciousness will be assessed in 20 healthy subjects using a random order 2-period (normal and altered state of consciousness) cross-over design. Alterations in consciousness will be induced by the hallucinogenic 5-hydroxytryptamine (HT)2A receptor agonist (5-HT2A) receptor agonist lysergic acid diethylamide (LSD).

Eligibility Criteria

Sex: All
Minimum Age: 25
Maximum Age: 65

More Details

NCT Number: NCT02308969
Acronym: 5HT2A-fMRI
Other IDs: EKNZ 2014-344
Study URL: https://ClinicalTrials.gov/show/NCT02308969
Last updated: Mar 23, 2022